The Company reports record net revenue and
gross profit in 2023 and achieves positive cash flow in the second
half of 2023
CALGARY,
AB, March 21, 2024 /CNW/ - SNDL Inc.
(NASDAQ: SNDL) ("SNDL" or the "Company") reported its
financial and operational results for the full year and fourth
quarter ended December 31, 2023. All
financial information in this press release is reported in millions
of Canadian dollars unless otherwise indicated.
SNDL has also posted a supplemental investor presentation and
shareholder letter on its website, found at https://sndl.com.
The Company will hold a conference call and webcast at
10 a.m. EDT (8
a.m. MDT) on Thursday, March 21,
2024. The conference call details can be found
below.
FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL AND OPERATIONAL
HIGHLIGHTS
- Record net revenue for 2023 of $909.0
million compared to $712.2
million in 2022, an increase of 28%. Net revenue for the
fourth quarter of 2023 was $248.5
million, compared to $240.4
million in the fourth quarter of 2022, an increase of 3%,
with sequential growth in the Cannabis Retail and Cannabis
Operations segments.
- Gross profit grew to a record $190.4
million, or 21% of sales, for 2023, compared to $140.4 million, or 20% of sales, in the previous
year, representing an increase of 36%. Record gross profit of
$57.3 million, or 23% of sales, for
the fourth quarter of 2023, compared to $43.6 million, or 18% of sales, in the fourth
quarter of 2022. This improvement underscores the benefit of our
supply chain optimization strategy, including the closure of the
Olds, Alberta cultivation facility
in October 2023.
- Cash flow was negative $84.5
million in 2023, compared to negative $278.7 million, a 70% year-over-year improvement.
In the fourth quarter of 2023, cash flow was negative $6.9 million, compared to negative $11.8 million in the fourth quarter of 2022, a
42% improvement. SNDL achieved positive cash flow in the second
half of 2023, totaling $9.6
million.
- Positive free cash flow1 achieved in the second half
of 2023, totaling $17.7 million. This
achievement was marked by positive free cash flow of $16.3 million in the third quarter of 2023 and
$1.4 million in the fourth quarter of
2023, despite the working capital build up in anticipation of the
holiday season in the latter quarter.
- Operating income loss of $162.8
million for 2023, partly attributable to restructuring
charges of $19.6 million and goodwill
impairment of $29.0 million. This
compares to a loss of $347.8 million
in the previous year, marking a 53% improvement driven by revenue
and margin expansion. Operating income loss of $84.9 million for the fourth quarter of 2023,
including $13.3 million of
restructuring cost and $29.0 million
of goodwill impairment, compared to a loss of $154.6 million in the fourth quarter of 2022, a
45% improvement.
- Adjusted EBITDA from continuing operations2 was
$29.2 million in 2023, compared to an
Adjusted EBITDA from continuing operations loss of $15.8 million in the previous year. Adjusted
EBITDA from continuing operations was $3.5
million for the fourth quarter of 2023, compared to an
Adjusted EBITDA from continuing operations loss of $7.5 million in the fourth quarter of 2022, a
147% improvement.
- 2023 was a transformational year for SNDL, laying the
groundwork for enhanced financial and operational performance in
2024 and beyond.
- Acquired The Valens Company Inc. ("Valens"),
creating a low-cost vertically integrated Canadian cannabis
company.
- Optimized the Cannabis Operations footprint by closing the
Olds, Alberta facility and
transitioning remaining cultivation activities to Atholville,
New Brunswick, while consolidating
manufacturing and processing activities in Kelowna, British Columbia.
- Optimized and rationalized the Company's cannabis brand and SKU
portfolio.
- Enhanced the proprietary data program in the Cannabis Retail
segment, significantly boosting margin profits.
- Enhanced the leadership team by appointing a new Chief
Financial Officer and President of Cannabis, among other key senior
roles.
- $766.7 million of unrestricted
cash, marketable securities and investments and no outstanding
debt, with $195 million of
unrestricted cash at December 31,
2023. SNDL has not raised cash through share offerings since
June 2021.
"2023 was a year of significant financial success for SNDL,
including record-breaking revenue and gross profit, and the
achievement of free cash flow in the second half of the year," said
Zach George, Chief Executive Officer
of SNDL. "The generation of stabilized free cash flow continues to
be a top priority for our team, and I am proud that we delivered on
this stated objective during the last two quarters. This period was
foundational as we acquired Valens, welcomed top-tier leaders and
streamlined our balance sheet, positioning SNDL for improved
performance in 2024 and beyond. In our Cannabis Operations, we
undertook a comprehensive overhaul, establishing a solid foundation
for future success. We refined our brand portfolio, optimized our
operational footprint, and enhanced our procurement strategies,
with early signs of a positive impact in 2024. We continued to
build on the Liquor Retail segment's stable base, focusing on
strategies that enhance margins through our data program, improved
inventory management, and emerging e-commerce program. We delivered
record results in revenue, gross profit, and cash flow within our
Cannabis Retail segment, driven by the expansion of both our owned
portfolio and network data programs. We also announced the launch
of SunStream USA Group through our
joint venture partner, SunStream Bancorp Inc., highlighting our
commitment to the U.S. market as a key catalyst for growth. Our
consumer-centric approach and relentless focus on quality is the
cornerstone of our strategy, supported by a strong balance sheet
and improving operations. This approach lays the groundwork for a
business positioned to create value for shareholders through
high-quality unadjusted earnings and robust free cash flow."
____________________________________
|
1 Free cash
flow is a non-IFRS financial measure that is not defined by IFRS
and, therefore, may not be comparable to similar measures reported
by other companies. See "Specified Financial Measures – Free Cash
Flow" below.
|
2 Adjusted
EBITDA from continuing operations is a non-IFRS financial measure
that is not defined by IFRS and, therefore, may not be comparable
to similar measures reported by other companies. See "Specified
Financial Measures – Adjusted EBITDA from continuing operations"
below.
|
|
FULL YEAR AND FOURTH QUARTER 2023 KEY FINANCIAL
METRICS
OPERATING
SEGMENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
($000s)
|
Liquor
Retail
|
|
Cannabis
Retail
|
|
Cannabis
Operations
|
|
Investments
|
|
Corporate
|
|
Total
|
|
Year ended
December 31, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
578,895
|
|
|
289,980
|
|
|
87,071
|
|
|
—
|
|
|
(46,940)
|
|
|
909,006
|
|
Gross profit
|
|
137,286
|
|
|
73,690
|
|
|
(20,561)
|
|
|
—
|
|
|
—
|
|
|
190,415
|
|
Operating income
(loss)
|
|
24,630
|
|
|
4,919
|
|
|
(112,445)
|
|
|
11,746
|
|
|
(91,668)
|
|
|
(162,818)
|
|
Adjusted operating
income (loss) (1)
|
|
24,630
|
|
|
4,919
|
|
|
(52,429)
|
|
|
11,746
|
|
|
(86,541)
|
|
|
(97,675)
|
|
Three months ended
December 31, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
159,493
|
|
|
75,152
|
|
|
26,044
|
|
|
—
|
|
|
(12,239)
|
|
|
248,450
|
|
Gross profit
|
|
38,396
|
|
|
20,045
|
|
|
(1,105)
|
|
|
—
|
|
|
—
|
|
|
57,336
|
|
Operating income
(loss)
|
|
10,102
|
|
|
(849)
|
|
|
(65,653)
|
|
|
(5,217)
|
|
|
(23,322)
|
|
|
(84,939)
|
|
Adjusted operating
income (loss) (1)
|
|
10,102
|
|
|
(849)
|
|
|
(7,619)
|
|
|
(5,217)
|
|
|
(23,433)
|
|
|
(27,016)
|
|
Year ended
December 31, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
462,180
|
|
|
205,610
|
|
|
44,407
|
|
|
—
|
|
|
—
|
|
|
712,197
|
|
Gross profit
|
|
106,307
|
|
|
47,334
|
|
|
(13,266)
|
|
|
—
|
|
|
—
|
|
|
140,375
|
|
Operating income
(loss)
|
|
20,619
|
|
|
(180,956)
|
|
|
(29,372)
|
|
|
(91,275)
|
|
|
(66,790)
|
|
|
(347,774)
|
|
Adjusted operating
income (loss) (1)
|
|
20,619
|
|
|
(8,347)
|
|
|
(27,522)
|
|
|
(91,945)
|
|
|
(66,790)
|
|
|
(173,985)
|
|
Three months ended
December 31, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
159,745
|
|
|
68,402
|
|
|
12,258
|
|
|
—
|
|
|
—
|
|
|
240,405
|
|
Gross profit
|
|
36,927
|
|
|
15,650
|
|
|
(9,009)
|
|
|
—
|
|
|
—
|
|
|
43,568
|
|
Operating income
(loss)
|
|
(3,898)
|
|
|
(98,444)
|
|
|
(12,442)
|
|
|
(19,543)
|
|
|
(20,319)
|
|
|
(154,646)
|
|
Adjusted operating
income (loss) (1)
|
|
(3,898)
|
|
|
(10,201)
|
|
|
(12,442)
|
|
|
(19,331)
|
|
|
(20,319)
|
|
|
(66,191)
|
|
(1)
Adjusted operating income (loss) is a non-IFRS financial measure
that is not defined by IFRS and, therefore may not
be comparable to similar measures reported by other companies.
See "Specified Financial Measures – Adjusted operating income
(loss)" below.
|
|
FULL YEAR AND FOURTH QUARTER 2023 RESULTS
SNDL's business is operated and reported in four segments:
Liquor Retail, Cannabis Retail, Cannabis Operations and
Investments.
Liquor Retail
SNDL is Canada's largest
private sector liquor retailer, operating 170 locations,
predominantly in Alberta, under its three retail banners:
"Wine and Beyond", "Liquor Depot" and "Ace
Liquor". Revenue comparisons for 2022 include operations
from March 31 to December 31, 2022,
following the acquisition of Alcanna Inc.
- Net revenue for Liquor Retail sales for the three banners
combined was $578.9 million in 2023,
compared to $462.2 million in 2022, a
25% increase year-over-year. Net revenue was $159.5 million in the fourth quarter of 2023,
showcasing consistent revenue compared to $159.7 million in the same quarter in the prior
year, driven by stable same-store sales.
- Gross profit in 2023 was $137.3
million, or 24% of sales, compared to $106.3 million, or 23% of sales, in 2022, a 29%
increase year-over-year. Gross profit was $38.4 million, or 24% of sales, in the fourth
quarter of 2023, compared to $36.9
million, or 23% of sales, in the fourth quarter of 2022.
This improvement was mainly driven by procurement productivity and
product mix management initiatives.
- SNDL launched its proprietary data licensing program for Liquor
Retail in the fourth quarter of 2023 and anticipates revenue
generation starting in the first quarter of 2024, helping to
further enhance the segment's profit margins.
- Private label sales, a substantial driver of profitable growth,
increased by 28% compared to the full year of 2022 and 28% compared
to the fourth quarter of 2022. This increase is driven by further
additions to the private label offerings, particularly within the
value segment. The Company plans to extend its private label
line-up with wine varietals sourced from distinguished regions and
notable winemakers, all priced attractively, which is expected to
contribute to SNDL's margin growth while further distinguishing its
liquor retail banners.
- The Company plans to open a Wine and Beyond location in
Airdrie, Alberta, in the second
quarter of 2024 to further build on the success of the
experiential, destination approach of the banner.
- As of March 21, 2024, the Ace
Liquor store count is 138, the Liquor Depot store count is 20, and
the Wine and Beyond store count is 12.
Cannabis Retail
With its 63% ownership interest in Nova Cannabis Inc.
("Nova"), SNDL is Canada's largest private-sector cannabis
retailer, operating 187 locations under its four retail banners:
"Value Buds", "Spiritleaf", "Superette", and
"Firesale Cannabis". SNDL's Cannabis Retail strategy is
based on several pillars, including the quality of its store
locations, its range of products, and the unique experiences it
provides customers. Using data and insights from a large volume of
monthly transactions enables SNDL to leverage technology and
analytics to inform and improve its retail strategy. Revenue
comparisons for 2022 include operations of Nova retail stores for
the period of March 31, 2022, to
December 31, 2022.
- Net revenue from the Cannabis Retail segment was a record
$290.0 million in 2023, compared to
$205.6 million in 2022, an increase
of 41% year-over-year. Net revenue in the fourth quarter of 2023
was $75.2 million, compared to
$68.4 million in the fourth quarter
of 2022, a 10% increase year-over-year in reported sales.
- For stores open in the fourth quarter of 2022 and 2023,
same-store sales increased 1.9%.
- Record gross profit from the Cannabis Retail segment, with
$73.7 million in 2023, or 25% of
sales, compared to $47.3 million in
2022, or 23% of sales, a 56% increase year-over-year. Gross profit
for the Cannabis Retail segment was $20.0
million, or 27% of sales, in the fourth quarter of 2023,
compared to $15.7 million, or 23% of
sales, in the fourth quarter of 2022, a 27% increase
year-over-year. The increase showcases the Company's efforts in
continued margin expansion initiatives.
- Nova's proprietary data licensing program generated revenue of
$12.3 million in 2023, compared to
$4.2 million in 2022, a 193% increase
year-over-year. Proprietary licensing revenues for the fourth
quarter of 2023 increased to $4.2
million.
- In February 2023, SNDL announced
the acquisition of five Superette stores in Ontario.
- As of March 21, 2024, the
Spiritleaf store count is 85 (21 corporate stores and 64 franchise
stores), the Superette store count is four corporate stores, the
Firesale Cannabis store count is two corporate stores and the Value
Buds store count is 96 corporate stores.
Cannabis Operations
SNDL has a diverse brand portfolio from value to premium,
emphasizing premium inhalable formats and a full suite of 2.0
products. With enhanced procurement capabilities and plans to
continue evolving toward a cost-effective cultivation and
manufacturing operation, the Cannabis Operations segment is a key
enabler of SNDL's vertical integration strategy. Cannabis
Operations include the operations of Valens for the period of
January 18, 2023, to December 31, 2023.
- The Cannabis Operations segment achieved a record net revenue
of $87.1 million in 2023, reflecting
a substantial 96% increase from $44.4
million in 2022. Net revenue for the fourth quarter of 2023
was $26.0 million, up 111% from
$12.3 million in the same quarter of
the previous year. The net revenue in the fourth quarter of 2023
represents the highest revenue achieved since Q3 2019, which was
$28.0 million, before market
saturation and price challenges.
- Gross margin was negative $20.6
million in 2023, compared to negative $13.3 million in 2022. Gross profit for the
fourth quarter of 2023 was negative $1.1
million, compared to negative $9.0
million in the fourth quarter of 2022. This 88% improvement
in gross profit during the fourth quarter is largely attributable
to the strategic decision to close the Olds, Alberta facility.
- During 2023, SNDL optimized its facility footprint to bolster
competitiveness and profitability. The Company is leveraging an
enhanced procurement strategy, while consolidating the remaining
cultivation activities at its Atholville,
New Brunswick facility, and centralizing manufacturing,
processing, and production operations in Kelowna, British Columbia.
- The Company undertook an intensive rationalization and
revitalization of its cannabis portfolio, reducing the SKU count
from 327 at the beginning of 2023 to 125 at the end of 2023 to
better focus on key consumer categories in vape, flower and
pre-rolls.
- SNDL monetized nearly 35 million grams of excess biomass,
strategically optimizing days-on-hand inventory.
- The Company has implemented innovative strategies in its
Atholville facility to improve
cultivation, resulting in an average annual yield of 104 grams per
square foot and an average THC potency result of 25%.
Investments
- For the year ended December 31,
2023, the Company had deployed capital to a portfolio of
cannabis-related investments with a carrying value of $571.6 million, including $538.3 million to SunStream.
- In 2023, the investment portfolio generated positive operating
income of $12.2 million compared to a
loss of $91.4 million for the
previous year. The interest and fee revenue for 2023 was
$14.0 million compared to
$16.7 million for the previous year.
Share of profit of equity-accounted investees for the year ended
December 31, 2023, was $6.8 million compared to a loss of $43.0 million for the year ended December 31, 2022.
- SunStream is a joint venture sponsored by SNDL. During 2023,
SunStream directed the formation of the SunStream USA group of companies ("SunStream
USA Group") in connection with
the restructuring of certain loans provided by SunStream. SunStream
USA Group is anticipated to be a
U.S. platform with one or more independent third-party investors,
which will be independently managed and governed. The SunStream
USA Group structure is anticipated
to be reviewed by the Nasdaq, as the relevant listing authority for
SNDL.
- At the end of the fourth quarter of 2023, the credit portfolio
controlled by SunStream comprised five investments: Jushi Holdings
Inc., SKYMINT Brands ("Skymint"), Ascend Wellness Holdings,
Surterra Holdings, Inc. d/b/a Parallel ("Parallel"), and
Columbia Care Inc.
- On September 22, 2023, an
affiliate of SunStream entered into restructuring arrangements
relating to investments in Parallel, which contemplate the
foreclosure, to a SunStream USA
entity, of certain Parallel cannabis operations in Florida, Massachusetts, Texas, and Nevada (the "Parallel
Transaction").
- On October 23, 2023, an affiliate
of SunStream announced a receivership court order granting the sale
of certain assets of Skymint to a SunStream USA Group entity (the "Skymint
Transaction").
- The Parallel Transaction and Skymint Transaction are
anticipated to close in 2024 and are subject to certain conditions
and regulatory approvals.
Equity Position
- $766.7 million of unrestricted
cash, marketable securities and investments, including investments
in equity-accounted investees, and no outstanding debt at
December 31, 2023, resulting in a net
book value of $1.2 billion.
- On November 13, 2023, the Company
announced that its board of directors had approved a renewal of the
share repurchase program upon its expiry on November 20, 2023. The Company's share repurchase
program continues to be available to lower the outstanding share
float. SNDL will continue to assess opportunities to utilize the
program to the extent that management believes it is in the best
interest of SNDL's shareholders. For the three months ended
December 31, 2023, the Company did
not purchase common shares for cancellation.
This press release is intended to be read in conjunction with
the Company's audited consolidated financial statements and the
notes thereto for the years ended December
31, 2023 and December 31,
2022, and the accompanying Management's Discussion and
Analysis ("MD&A"). These documents are available under
the Company's profile on SEDAR+ at www.sedarplus.ca and EDGAR
at www.sec.gov/edgar.shtml.
CONFERENCE CALL
The Company will hold a conference call and webcast at
10 a.m. EDT (8
a.m. MDT) on Thursday, March 21,
2024.
WEBCAST ACCESS
To access the live webcast of the call, please visit the
following link:
https://services.choruscall.ca/links/sndl2023q4.html
REPLAY
A telephone replay will be available for one month. To access
the replay, dial:
Canada/USA Toll Free: 1-800-319-6413 or International
Toll: +1-604-638-9010
When prompted, enter Replay Access Code: 0739 #
The webcast archive will be available for three months via the link
provided above.
ABOUT SNDL INC.
SNDL is a public company whose shares are traded on the Nasdaq
under the symbol "SNDL." SNDL is the largest private-sector
liquor and cannabis retailer in Canada with retail banners that include Ace
Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and
Firesale Cannabis. SNDL is a licensed cannabis producer and one of
the largest vertically integrated cannabis companies in
Canada specializing in low-cost
biomass sourcing, premium indoor cultivation, product innovation,
low-cost manufacturing facilities, and a cannabis brand portfolio
that includes Top Leaf, Contraband, Palmetto, Bon Jak, Versus,
Value Buds, and Vacay. SNDL's investment portfolio seeks to deploy
strategic capital through direct and indirect investments and
partnerships throughout the North American cannabis industry. For
more information on SNDL, please go to https://sndl.com/.
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"), including,
but not limited to, statements regarding the Company's operational
goals, the Company's ability to achieve improved profitability,
growth and efficiencies across all segments, or its goal of
sustainable, positive gross margin and positive free cash flow,
revenue generation from the Liquor Retail proprietary data
licensing program, expansion of product offerings (including the
expected expansion of the Company's wine private label), the impact
of rationalization initiatives on revenue and margins within the
Cannabis Operations segment and owned retail locations, the
expansion and additional cost savings at the Atholville facility, performance of the
Company's investments, including through the SunStream joint
venture and SunStream USA Group,
the receipt of regulatory and listing authority approvals necessary
to implement the proposed SunStream USA Group investment structure, the ability to
realize expected cost savings in relation to the Valens
Acquisition, expected run-rate synergies and expected proceeds from
future asset sales, and any other potential forms of shareholder
value creation. Forward-looking statements are frequently
characterized by words such as "aim", "anticipate", "assume",
"believe", "contemplate", "continue", "could", "due", "estimate",
"expect", "goal", "intend", "may", "objective", "plan", "predict",
"potential", "positioned", "pioneer", "seek", "should", "target",
"will", "would", and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. These forward-looking
statements are based on current expectations, estimates, forecasts
and projections about the Company's business and the industry in
which it operates and management's beliefs and assumptions and are
not guarantees of future performance or development and involve
known and unknown risks, uncertainties and other factors that are
in some cases beyond its control. Forward-looking statements are
based on the opinions and estimates of management at the date the
statements are made and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. Please see "Risk Factors" in
the Company's Annual Information Form dated March 20, 2024, and the risk factors included in
our other public disclosure documents for a discussion of the
material risk factors that could cause actual results to differ
materially from the forward-looking information. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
Consolidated Statement of Loss and
Comprehensive Loss
(Expressed in thousands of Canadian
dollars, except per share amounts)
|
|
Year
ended
December 31
|
|
|
|
2023
|
|
|
2022
|
|
Gross
revenue
|
|
|
957,725
|
|
|
|
729,694
|
|
Excise taxes
|
|
|
48,719
|
|
|
|
17,497
|
|
Net
revenue
|
|
|
909,006
|
|
|
|
712,197
|
|
Cost of
sales
|
|
|
689,338
|
|
|
|
558,089
|
|
Inventory impairment
and obsolescence
|
|
|
30,644
|
|
|
|
7,012
|
|
Gross profit before
fair value adjustments
|
|
|
189,024
|
|
|
|
147,096
|
|
Change in fair value of
biological assets
|
|
|
(7,936)
|
|
|
|
(1,309)
|
|
Change in fair value
realized through inventory
|
|
|
9,327
|
|
|
|
(5,412)
|
|
Gross
profit
|
|
|
190,415
|
|
|
|
140,375
|
|
|
|
|
|
|
|
|
|
|
Interest and fee
revenue
|
|
|
14,517
|
|
|
|
16,739
|
|
Investment
loss
|
|
|
(9,258)
|
|
|
|
(65,164)
|
|
Share of profit (loss)
of equity-accounted investees
|
|
|
6,758
|
|
|
|
(43,002)
|
|
|
|
|
|
|
|
|
|
|
General and
administrative
|
|
|
199,725
|
|
|
|
140,168
|
|
Sales and
marketing
|
|
|
15,045
|
|
|
|
8,417
|
|
Research and
development
|
|
|
324
|
|
|
|
2,448
|
|
Depreciation and
amortization
|
|
|
60,216
|
|
|
|
40,945
|
|
Share-based
compensation
|
|
|
15,400
|
|
|
|
9,671
|
|
Restructuring costs
(recovery)
|
|
|
19,573
|
|
|
|
(670)
|
|
Asset
impairment
|
|
|
54,967
|
|
|
|
196,033
|
|
Gain on cancellation of
contracts
|
|
|
—
|
|
|
|
(290)
|
|
Operating income
(loss)
|
|
|
(162,818)
|
|
|
|
(347,774)
|
|
|
|
|
|
|
|
|
|
|
Transaction
costs
|
|
|
(3,718)
|
|
|
|
(1,352)
|
|
Finance costs,
net
|
|
|
(11,362)
|
|
|
|
(41,314)
|
|
Change in estimate of
fair value of derivative warrants
|
|
|
6,602
|
|
|
|
10,783
|
|
Foreign exchange
loss
|
|
|
(367)
|
|
|
|
(19)
|
|
Loss on disposition of
assets
|
|
|
(353)
|
|
|
|
(94)
|
|
Loss before income
tax
|
|
|
(172,016)
|
|
|
|
(379,770)
|
|
Income tax
recovery
|
|
|
—
|
|
|
|
7,342
|
|
Net loss from
continuing operations
|
|
|
(172,016)
|
|
|
|
(372,428)
|
|
Net loss from
discontinued operations
|
|
|
(4,535)
|
|
|
|
—
|
|
Net
loss
|
|
|
(176,551)
|
|
|
|
(372,428)
|
|
|
|
|
|
|
|
|
|
|
Equity-accounted
investees - share of other comprehensive income (loss)
|
|
|
(12,771)
|
|
|
|
24,581
|
|
Comprehensive
loss
|
|
|
(189,322)
|
|
|
|
(347,847)
|
|
|
|
|
|
|
|
|
|
|
Net loss from
continuing operations attributable to:
|
|
|
|
|
|
|
|
|
Owners of the
Company
|
|
|
(168,125)
|
|
|
|
(335,114)
|
|
Non-controlling
interest
|
|
|
(3,891)
|
|
|
|
(37,314)
|
|
|
|
|
(172,016)
|
|
|
|
(372,428)
|
|
Net loss
attributable to:
|
|
|
|
|
|
|
|
|
Owners of the
Company
|
|
|
(172,660)
|
|
|
|
(335,114)
|
|
Non-controlling
interest
|
|
|
(3,891)
|
|
|
|
(37,314)
|
|
|
|
|
(176,551)
|
|
|
|
(372,428)
|
|
Comprehensive loss
attributable to:
|
|
|
|
|
|
|
|
|
Owners of the
Company
|
|
|
(185,431)
|
|
|
|
(310,533)
|
|
Non-controlling
interest
|
|
|
(3,891)
|
|
|
|
(37,314)
|
|
Consolidated Statement of Financial
Position
(Expressed in thousands of Canadian dollars)
As at
|
December 31,
2023
|
|
December 31,
2022
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
195,041
|
|
|
279,586
|
|
Restricted
cash
|
|
19,891
|
|
|
19,338
|
|
Marketable
securities
|
|
225
|
|
|
21,926
|
|
Accounts
receivable
|
|
27,059
|
|
|
22,636
|
|
Biological
assets
|
|
429
|
|
|
3,477
|
|
Inventory
|
|
129,060
|
|
|
127,782
|
|
Prepaid expenses and
deposits
|
|
22,464
|
|
|
10,110
|
|
Investments
|
|
3,400
|
|
|
6,552
|
|
Assets held for
sale
|
|
6,375
|
|
|
6,375
|
|
Net investment in
subleases
|
|
2,970
|
|
|
3,701
|
|
|
|
406,914
|
|
|
501,483
|
|
Non-current
assets
|
|
|
|
|
|
|
Long-term deposits and
receivables
|
|
4,837
|
|
|
8,584
|
|
Right of use
assets
|
|
129,679
|
|
|
134,154
|
|
Property, plant and
equipment
|
|
152,916
|
|
|
143,409
|
|
Net investment in
subleases
|
|
18,396
|
|
|
19,618
|
|
Intangible
assets
|
|
73,149
|
|
|
74,885
|
|
Investments
|
|
29,660
|
|
|
90,702
|
|
Equity-accounted
investees
|
|
538,331
|
|
|
519,255
|
|
Goodwill
|
|
119,282
|
|
|
67,260
|
|
Total
assets
|
|
1,473,164
|
|
|
1,559,350
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
Accounts payable and
accrued liabilities
|
|
68,210
|
|
|
48,153
|
|
Lease
liabilities
|
|
30,537
|
|
|
30,206
|
|
Derivative
warrants
|
|
4,400
|
|
|
11,002
|
|
|
|
103,147
|
|
|
89,361
|
|
Non-current
liabilities
|
|
|
|
|
|
|
Lease
liabilities
|
|
136,492
|
|
|
139,625
|
|
Other
liabilities
|
|
4,185
|
|
|
2,709
|
|
Total
liabilities
|
|
243,824
|
|
|
231,695
|
|
|
|
|
|
|
|
|
Shareholders'
equity
|
|
|
|
|
|
|
Share
capital
|
|
2,375,950
|
|
|
2,292,810
|
|
Warrants
|
|
2,260
|
|
|
2,260
|
|
Contributed
surplus
|
|
73,014
|
|
|
68,961
|
|
Contingent
consideration
|
|
2,279
|
|
|
2,279
|
|
Accumulated
deficit
|
|
(1,260,851)
|
|
|
(1,091,999)
|
|
Accumulated other
comprehensive income
|
|
19,417
|
|
|
32,188
|
|
Total shareholders'
equity
|
|
1,212,069
|
|
|
1,306,499
|
|
Non-controlling
interest
|
|
17,271
|
|
|
21,156
|
|
Total liabilities
and shareholders' equity
|
|
1,473,164
|
|
|
1,559,350
|
|
Consolidated Statement of Cash
Flows
(Expressed in thousands of Canadian dollars)
|
|
Year
ended
December 31
|
|
|
|
2023
|
|
|
2022
|
|
Cash provided by
(used in):
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
|
|
|
|
|
|
|
Net loss for the
period
|
|
|
(176,551)
|
|
|
|
(372,428)
|
|
Adjustments
for:
|
|
|
|
|
|
|
|
|
Income tax
recovery
|
|
|
—
|
|
|
|
(7,342)
|
|
Interest and fee
revenue
|
|
|
(14,517)
|
|
|
|
(16,739)
|
|
Change in fair value
of biological assets
|
|
|
7,936
|
|
|
|
1,309
|
|
Share-based
compensation
|
|
|
15,400
|
|
|
|
9,671
|
|
Depreciation and
amortization
|
|
|
64,946
|
|
|
|
47,322
|
|
Loss on disposition of
assets
|
|
|
353
|
|
|
|
94
|
|
Inventory impairment
and obsolescence
|
|
|
30,644
|
|
|
|
7,012
|
|
Finance costs,
net
|
|
|
11,362
|
|
|
|
41,314
|
|
Change in estimate of
fair value of derivative warrants
|
|
|
(6,602)
|
|
|
|
(10,783)
|
|
Unrealized foreign
exchange gain
|
|
|
(13)
|
|
|
|
(16)
|
|
Transaction
costs
|
|
|
1,221
|
|
|
|
—
|
|
Asset
impairment
|
|
|
54,967
|
|
|
|
196,033
|
|
Share of (profit) loss
of equity-accounted investees
|
|
|
(6,758)
|
|
|
|
43,002
|
|
Realized loss on
settlement of marketable securities
|
|
|
138,874
|
|
|
|
—
|
|
Unrealized (gain) loss
on marketable securities
|
|
|
(129,616)
|
|
|
|
65,553
|
|
Additions to
marketable securities
|
|
|
—
|
|
|
|
(3,500)
|
|
Proceeds from
settlement of marketable securities
|
|
|
6,704
|
|
|
|
—
|
|
Income distributions
from equity-accounted investees
|
|
|
—
|
|
|
|
1,661
|
|
Interest
received
|
|
|
13,563
|
|
|
|
13,403
|
|
Exercise of
cash-settled deferred share units
|
|
|
—
|
|
|
|
(204)
|
|
Change in non-cash
working capital
|
|
|
(32,875)
|
|
|
|
(22,073)
|
|
Net cash used in
operating activities from continuing operations
|
|
|
(20,962)
|
|
|
|
(6,711)
|
|
Net cash provided by
operating activities from discontinued operations
|
|
|
4,314
|
|
|
|
—
|
|
Net cash used in
operating activities
|
|
|
(16,648)
|
|
|
|
(6,711)
|
|
Investing
activities
|
|
|
|
|
|
|
|
|
Additions to property,
plant and equipment
|
|
|
(7,845)
|
|
|
|
(10,666)
|
|
Additions to
intangible assets
|
|
|
(87)
|
|
|
|
(197)
|
|
Additions to
investments
|
|
|
(732)
|
|
|
|
(75,598)
|
|
Additions to
equity-accounted investees
|
|
|
(25,089)
|
|
|
|
(119,137)
|
|
Proceeds from disposal
of property, plant and equipment
|
|
|
1,213
|
|
|
|
4,000
|
|
Acquisitions, net of
cash acquired
|
|
|
3,695
|
|
|
|
(28,640)
|
|
Change in non-cash
working capital
|
|
|
4,028
|
|
|
|
74
|
|
Net cash used in
investing activities from continuing operations
|
|
|
(24,817)
|
|
|
|
(230,164)
|
|
Net cash used in
investing activities from discontinued operations
|
|
|
—
|
|
|
|
—
|
|
Net cash used in
investing activities
|
|
|
(24,817)
|
|
|
|
(230,164)
|
|
Financing
activities
|
|
|
|
|
|
|
|
|
Change in restricted
cash
|
|
|
(553)
|
|
|
|
7,675
|
|
Payments on lease
liabilities, net
|
|
|
(41,013)
|
|
|
|
(27,693)
|
|
Repurchase of common
shares, net of costs
|
|
|
(1,536)
|
|
|
|
(13,390)
|
|
Proceeds from issuance
of shares, net of costs
|
|
|
—
|
|
|
|
22
|
|
Distributions declared
by subsidiaries
|
|
|
(20)
|
|
|
|
(24)
|
|
Repayment of long-term
debt
|
|
|
—
|
|
|
|
(10,000)
|
|
Change in non-cash
working capital
|
|
|
42
|
|
|
|
1,620
|
|
Net cash used in
financing activities from continuing operations
|
|
|
(43,080)
|
|
|
|
(41,790)
|
|
Net cash used in
financing activities from discontinued operations
|
|
|
—
|
|
|
|
—
|
|
Net cash used in
financing activities
|
|
|
(43,080)
|
|
|
|
(41,790)
|
|
Change in cash and cash
equivalents
|
|
|
(84,545)
|
|
|
|
(278,665)
|
|
Cash and cash
equivalents, beginning of period
|
|
|
279,586
|
|
|
|
558,251
|
|
Cash and cash
equivalents, end of period
|
|
|
195,041
|
|
|
|
279,586
|
|
SPECIFIED FINANCIAL MEASURES
Certain specified financial measures in this news release are
non-IFRS measures. These terms are not defined by IFRS and,
therefore, may not be comparable to similar measures reported by
other companies. These non-IFRS financial measures should not be
considered in isolation or as an alternative for or superior to
measures of performance prepared in accordance with IFRS. These
measures are presented and described in order to provide
shareholders and potential investors with additional measures in
understanding the Company's operating results in the same manner as
the management team.
ADJUSTED EBITDA FROM CONTINUING OPERATIONS
Adjusted EBITDA from continuing operations is a non-IFRS financial
measure which the Company uses to evaluate its operating
performance. Adjusted EBITDA from continuing operations provides
information to investors, analysts, and others to aid in
understanding and evaluating the Company's operating results in a
similar manner to its management team. The Company defines adjusted
EBITDA from continuing operations as net earnings (loss) from
continuing operations before finance costs, change in estimate of
fair value of derivative warrants, depreciation and amortization,
loss (gain) on cancellation of contracts, income tax expense
(recovery) and excluding change in fair value of biological assets,
change in fair value realized through inventory, unrealized foreign
exchange gains or losses, unrealized gains or losses on marketable
securities, realized gains or losses on marketable securities,
share-based compensation expense, asset impairment, gain or loss on
disposal of property, plant and equipment, cost of sales non-cash
component, inventory impairment (recovery) and obsolescence,
restructuring costs (recovery) and transaction costs. The Company
presents both consolidated or total adjusted EBITDA from continuing
operations and adjusted EBITDA from continuing operations by
operating segment.
OPERATING
SEGMENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
($000s)
|
Liquor
Retail
|
|
Cannabis
Retail
|
|
Cannabis
Operations
|
|
Investments
|
|
Corporate
|
|
Total
|
|
Year ended
December 31, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
from continuing operations
|
|
19,190
|
|
|
1,310
|
|
|
(112,159)
|
|
|
8,429
|
|
|
(88,786)
|
|
|
(172,016)
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance
costs
|
|
5,274
|
|
|
3,526
|
|
|
(755)
|
|
|
3,317
|
|
|
—
|
|
|
11,362
|
|
Change in estimate of
fair value of derivative
warrants
|
|
—
|
|
|
(2)
|
|
|
—
|
|
|
—
|
|
|
(6,600)
|
|
|
(6,602)
|
|
Depreciation and
amortization
|
|
35,662
|
|
|
15,820
|
|
|
3,835
|
|
|
—
|
|
|
4,899
|
|
|
60,216
|
|
Change in fair value
of biological assets
|
|
—
|
|
|
—
|
|
|
7,936
|
|
|
—
|
|
|
—
|
|
|
7,936
|
|
Change in fair value
realized through
inventory
|
|
—
|
|
|
—
|
|
|
(9,327)
|
|
|
—
|
|
|
—
|
|
|
(9,327)
|
|
Unrealized foreign
exchange (gain) loss
|
|
(2)
|
|
|
—
|
|
|
(11)
|
|
|
—
|
|
|
—
|
|
|
(13)
|
|
Unrealized (gain) loss
on marketable
securities
|
|
—
|
|
|
—
|
|
|
651
|
|
|
(130,267)
|
|
|
—
|
|
|
(129,616)
|
|
Realized loss on
marketable securities
|
|
—
|
|
|
—
|
|
|
—
|
|
|
138,874
|
|
|
—
|
|
|
138,874
|
|
Share-based
compensation
|
|
—
|
|
|
6
|
|
|
—
|
|
|
—
|
|
|
15,394
|
|
|
15,400
|
|
Asset
impairment
|
|
1,640
|
|
|
5,047
|
|
|
48,280
|
|
|
—
|
|
|
—
|
|
|
54,967
|
|
Loss (gain) on
disposition of PP&E
|
|
(25)
|
|
|
79
|
|
|
299
|
|
|
—
|
|
|
—
|
|
|
353
|
|
Cost of sales non-cash
component (1)
|
|
—
|
|
|
—
|
|
|
3,736
|
|
|
—
|
|
|
—
|
|
|
3,736
|
|
Inventory impairment
(recovery) and
obsolescence
|
|
—
|
|
|
—
|
|
|
30,644
|
|
|
—
|
|
|
—
|
|
|
30,644
|
|
Restructuring costs
(recovery)
|
|
—
|
|
|
—
|
|
|
14,446
|
|
|
—
|
|
|
5,127
|
|
|
19,573
|
|
Transaction
costs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,718
|
|
|
3,718
|
|
Adjusted EBITDA from
continuing operations
|
|
61,739
|
|
|
25,786
|
|
|
(12,425)
|
|
|
20,353
|
|
|
(66,248)
|
|
|
29,205
|
|
(1) Cost of sales
non-cash component is comprised of depreciation expense
|
|
OPERATING
SEGMENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
($000s)
|
Liquor
Retail
|
|
Cannabis
Retail
|
|
Cannabis
Operations
|
|
Investments
|
|
Corporate
|
|
Total
|
|
Three months ended
December 31, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
from continuing operations
|
|
8,990
|
|
|
(1,920)
|
|
|
(65,434)
|
|
|
(4,858)
|
|
|
(22,201)
|
|
|
(85,423)
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance
costs
|
|
1,121
|
|
|
1,070
|
|
|
(243)
|
|
|
(359)
|
|
|
—
|
|
|
1,589
|
|
Change in estimate of
fair value of derivative
warrants
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2,400)
|
|
|
(2,400)
|
|
Depreciation and
amortization
|
|
7,719
|
|
|
4,429
|
|
|
1,085
|
|
|
—
|
|
|
1,527
|
|
|
14,760
|
|
Change in fair value
of biological assets
|
|
—
|
|
|
—
|
|
|
1,169
|
|
|
—
|
|
|
—
|
|
|
1,169
|
|
Change in fair value
realized through
inventory
|
|
—
|
|
|
—
|
|
|
(3,999)
|
|
|
—
|
|
|
—
|
|
|
(3,999)
|
|
Unrealized foreign
exchange (gain) loss
|
|
—
|
|
|
—
|
|
|
(57)
|
|
|
—
|
|
|
—
|
|
|
(57)
|
|
Unrealized (gain) loss
on marketable
securities
|
|
—
|
|
|
—
|
|
|
40
|
|
|
—
|
|
|
—
|
|
|
40
|
|
Realized loss on
marketable securities
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Share-based
compensation
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,925
|
|
|
3,925
|
|
Asset
impairment
|
|
—
|
|
|
4,481
|
|
|
46,238
|
|
|
—
|
|
|
—
|
|
|
50,719
|
|
Loss (gain) on
disposition of PP&E
|
|
(18)
|
|
|
—
|
|
|
96
|
|
|
—
|
|
|
—
|
|
|
78
|
|
Cost of sales non-cash
component (1)
|
|
—
|
|
|
—
|
|
|
462
|
|
|
—
|
|
|
—
|
|
|
462
|
|
Inventory impairment
(recovery) and
obsolescence
|
|
—
|
|
|
—
|
|
|
8,050
|
|
|
—
|
|
|
—
|
|
|
8,050
|
|
Restructuring costs
(recovery)
|
|
—
|
|
|
—
|
|
|
13,398
|
|
|
—
|
|
|
(111)
|
|
|
13,287
|
|
Transaction
costs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,279
|
|
|
1,279
|
|
Adjusted EBITDA from
continuing operations
|
|
17,812
|
|
|
8,060
|
|
|
805
|
|
|
(5,217)
|
|
|
(17,981)
|
|
|
3,479
|
|
(1) Cost of sales
non-cash component is comprised of depreciation expense
|
|
OPERATING
SEGMENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
($000s)
|
Liquor
Retail
|
|
Cannabis
Retail
|
|
Cannabis
Operations
|
|
Investments
|
|
Corporate
|
|
Total
|
|
Year ended
December 31, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
from continuing operations
|
|
17,726
|
|
|
(183,055)
|
|
|
(29,618)
|
|
|
(120,020)
|
|
|
(57,461)
|
|
|
(372,428)
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance
costs
|
|
2,845
|
|
|
2,155
|
|
|
227
|
|
|
36,087
|
|
|
—
|
|
|
41,314
|
|
Change in estimate of
fair value of derivative
warrants
|
|
—
|
|
|
(83)
|
|
|
—
|
|
|
—
|
|
|
(10,700)
|
|
|
(10,783)
|
|
Loss (gain) on
cancellation of contracts
|
|
—
|
|
|
—
|
|
|
(290)
|
|
|
—
|
|
|
—
|
|
|
(290)
|
|
Depreciation and
amortization
|
|
17,025
|
|
|
9,920
|
|
|
199
|
|
|
—
|
|
|
13,801
|
|
|
40,945
|
|
Income tax
recovery
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(7,342)
|
|
|
—
|
|
|
(7,342)
|
|
Change in fair value
of biological assets
|
|
—
|
|
|
—
|
|
|
1,309
|
|
|
—
|
|
|
—
|
|
|
1,309
|
|
Change in fair value
realized through
inventory
|
|
—
|
|
|
—
|
|
|
5,412
|
|
|
—
|
|
|
—
|
|
|
5,412
|
|
Unrealized foreign
exchange (gain) loss
|
|
10
|
|
|
(4)
|
|
|
(22)
|
|
|
—
|
|
|
—
|
|
|
(16)
|
|
Unrealized (gain) loss
on marketable
securities
|
|
—
|
|
|
—
|
|
|
—
|
|
|
65,553
|
|
|
—
|
|
|
65,553
|
|
Share-based
compensation
|
|
—
|
|
|
297
|
|
|
—
|
|
|
—
|
|
|
9,374
|
|
|
9,671
|
|
Asset
impairment
|
|
10,079
|
|
|
181,665
|
|
|
4,289
|
|
|
—
|
|
|
—
|
|
|
196,033
|
|
Loss (gain) on
disposition of PP&E
|
|
48
|
|
|
27
|
|
|
19
|
|
|
—
|
|
|
—
|
|
|
94
|
|
Cost of sales non-cash
component (1)
|
|
—
|
|
|
—
|
|
|
7,003
|
|
|
—
|
|
|
—
|
|
|
7,003
|
|
Inventory impairment
(recovery) and
obsolescence
|
|
—
|
|
|
—
|
|
|
7,012
|
|
|
—
|
|
|
—
|
|
|
7,012
|
|
Restructuring costs
(recovery)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(670)
|
|
|
—
|
|
|
(670)
|
|
Transaction
costs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,352
|
|
|
1,352
|
|
Adjusted EBITDA from
continuing operations
|
|
47,733
|
|
|
10,922
|
|
|
(4,460)
|
|
|
(26,392)
|
|
|
(43,634)
|
|
|
(15,831)
|
|
(1) Cost of sales
non-cash component is comprised of depreciation expense
|
|
OPERATING
SEGMENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
($000s)
|
Liquor
Retail
|
|
Cannabis
Retail
|
|
Cannabis
Operations
|
|
Investments
|
|
Corporate
|
|
Total
|
|
Three months ended
December 31, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
from continuing operations
|
|
(1,316)
|
|
|
(98,374)
|
|
|
(12,932)
|
|
|
(30,017)
|
|
|
(18,932)
|
|
|
(161,571)
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance
costs
|
|
(2,599)
|
|
|
(57)
|
|
|
19
|
|
|
9,098
|
|
|
—
|
|
|
6,461
|
|
Change in estimate of
fair value of derivative
warrants
|
|
—
|
|
|
(27)
|
|
|
—
|
|
|
—
|
|
|
(3,900)
|
|
|
(3,927)
|
|
Loss (gain) on
cancellation of contracts
|
|
—
|
|
|
—
|
|
|
(290)
|
|
|
—
|
|
|
—
|
|
|
(290)
|
|
Depreciation and
amortization
|
|
11,303
|
|
|
3,879
|
|
|
190
|
|
|
—
|
|
|
6,251
|
|
|
21,623
|
|
Income tax
recovery
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,376
|
|
|
—
|
|
|
1,376
|
|
Change in fair value
of biological assets
|
|
—
|
|
|
—
|
|
|
2,712
|
|
|
—
|
|
|
—
|
|
|
2,712
|
|
Change in fair value
realized through
inventory
|
|
—
|
|
|
—
|
|
|
279
|
|
|
—
|
|
|
—
|
|
|
279
|
|
Unrealized foreign
exchange (gain) loss
|
|
3
|
|
|
(4)
|
|
|
25
|
|
|
—
|
|
|
—
|
|
|
24
|
|
Unrealized (gain) loss
on marketable
securities
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,868
|
|
|
—
|
|
|
6,868
|
|
Share-based
compensation
|
|
—
|
|
|
372
|
|
|
—
|
|
|
—
|
|
|
2,588
|
|
|
2,960
|
|
Asset
impairment
|
|
10,079
|
|
|
97,299
|
|
|
283
|
|
|
—
|
|
|
—
|
|
|
107,661
|
|
Loss (gain) on
disposition of PP&E
|
|
17
|
|
|
14
|
|
|
471
|
|
|
—
|
|
|
—
|
|
|
502
|
|
Cost of sales non-cash
component (1)
|
|
—
|
|
|
—
|
|
|
1,702
|
|
|
—
|
|
|
—
|
|
|
1,702
|
|
Inventory impairment
(recovery) and
obsolescence
|
|
—
|
|
|
—
|
|
|
3,467
|
|
|
—
|
|
|
—
|
|
|
3,467
|
|
Restructuring costs
(recovery)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
212
|
|
|
—
|
|
|
212
|
|
Transaction
costs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,392
|
|
|
2,392
|
|
Adjusted EBITDA from
continuing operations
|
|
17,487
|
|
|
3,102
|
|
|
(4,074)
|
|
|
(12,463)
|
|
|
(11,601)
|
|
|
(7,549)
|
|
(1) Cost of sales
non-cash component is comprised of depreciation expense
|
|
ADJUSTED OPERATING INCOME (LOSS)
Adjusted operating
income (loss) a non-IFRS financial measure which the Company uses
to evaluate its operating performance. Adjusted operating income
(loss) provides information to investors, analysts, and others to
aid in understanding and evaluating the Company's operating results
in a similar manner to its management team. The Company defines
adjusted operating income (loss) as operating income (loss) less
restructuring costs (recovery) goodwill and intangible asset
impairments and asset impairments triggered by restructuring
activities.
($000s)
|
Liquor
Retail
|
|
Cannabis
Retail
|
|
Cannabis
Operations
|
|
Investments
|
|
Corporate
|
|
Total
|
|
Three months ended
December 31, 2023
|
|
Operating income
(loss)
|
|
10,102
|
|
|
(849)
|
|
|
(65,653)
|
|
|
(5,217)
|
|
|
(23,322)
|
|
|
(84,939)
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring costs
(recovery)
|
|
—
|
|
|
—
|
|
|
13,398
|
|
|
—
|
|
|
(111)
|
|
|
13,287
|
|
Intangible asset
impairments
|
|
—
|
|
|
—
|
|
|
29,000
|
|
|
—
|
|
|
—
|
|
|
29,000
|
|
Impairments triggered
by restructuring
|
|
—
|
|
|
—
|
|
|
15,636
|
|
|
—
|
|
|
—
|
|
|
15,636
|
|
Adjusted operating
income (loss)
|
|
10,102
|
|
|
(849)
|
|
|
(7,619)
|
|
|
(5,217)
|
|
|
(23,433)
|
|
|
(27,016)
|
|
($000s)
|
Liquor
Retail
|
|
Cannabis
Retail
|
|
Cannabis
Operations
|
|
Investments
|
|
Corporate
|
|
Total
|
|
Three months ended
December 31, 2022
|
|
Operating income
(loss)
|
|
(3,898)
|
|
|
(98,444)
|
|
|
(12,442)
|
|
|
(19,543)
|
|
|
(20,319)
|
|
|
(154,646)
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring
costs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
212
|
|
|
—
|
|
|
212
|
|
Intangible asset
impairments
|
|
—
|
|
|
88,243
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
88,243
|
|
Adjusted operating
income (loss)
|
|
(3,898)
|
|
|
(10,201)
|
|
|
(12,442)
|
|
|
(19,331)
|
|
|
(20,319)
|
|
|
(66,191)
|
|
($000s)
|
Liquor
Retail
|
|
Cannabis
Retail
|
|
Cannabis
Operations
|
|
Investments
|
|
Corporate
|
|
Total
|
|
Year ended
December 31, 2023
|
|
Operating income
(loss)
|
|
24,630
|
|
|
4,919
|
|
|
(112,445)
|
|
|
11,746
|
|
|
(91,668)
|
|
|
(162,818)
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring
costs
|
|
—
|
|
|
—
|
|
|
14,446
|
|
|
—
|
|
|
5,127
|
|
|
19,573
|
|
Intangible asset
impairments
|
|
—
|
|
|
—
|
|
|
29,934
|
|
|
—
|
|
|
—
|
|
|
29,934
|
|
Impairments triggered
by restructuring
|
|
—
|
|
|
—
|
|
|
15,636
|
|
|
—
|
|
|
—
|
|
|
15,636
|
|
Adjusted operating
income (loss)
|
|
24,630
|
|
|
4,919
|
|
|
(52,429)
|
|
|
11,746
|
|
|
(86,541)
|
|
|
(97,675)
|
|
($000s)
|
Liquor
Retail
|
|
Cannabis
Retail
|
|
Cannabis
Operations
|
|
Investments
|
|
Corporate
|
|
Total
|
|
Year ended
December 31, 2022
|
|
Operating income
(loss)
|
|
20,619
|
|
|
(180,956)
|
|
|
(29,372)
|
|
|
(91,275)
|
|
|
(66,790)
|
|
|
(347,774)
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring costs
(recovery)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(670)
|
|
|
—
|
|
|
(670)
|
|
Intangible asset
impairments
|
|
—
|
|
|
172,609
|
|
|
1,850
|
|
|
—
|
|
|
—
|
|
|
174,459
|
|
Adjusted operating
income (loss)
|
|
20,619
|
|
|
(8,347)
|
|
|
(27,522)
|
|
|
(91,945)
|
|
|
(66,790)
|
|
|
(173,985)
|
|
FREE CASH FLOW
Free cash flow is a non-IFRS financial measure which the Company
uses to evaluate its financial performance. Free cash flow provides
information which management believes to be useful to investors,
analysts and others in understanding and evaluating the Company's
ability to generate positive cash flows as it removes cash used for
non-operational items. The Company defines free cash flow as the
total change in cash and cash equivalents less cash used for common
share repurchases, dividends (if any), changes to debt instruments,
changes to long-term investments, net cash used for acquisitions
plus cash provided by dispositions (if any).
|
Three months
ended
December 31
|
|
Year
ended
December 31
|
|
($000s)
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
Change in cash and cash
equivalents
|
|
(6,942)
|
|
|
(11,841)
|
|
|
(84,545)
|
|
|
(278,665)
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
Repurchase of common
shares
|
|
—
|
|
|
7,241
|
|
|
1,536
|
|
|
13,390
|
|
Changes to debt
instruments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
10,000
|
|
Changes to long-term
investments
|
|
8,325
|
|
|
17,693
|
|
|
25,821
|
|
|
194,735
|
|
Acquisitions, net of
cash acquired
|
|
—
|
|
|
(2,509)
|
|
|
(3,695)
|
|
|
28,640
|
|
Free cash
flow
|
|
1,383
|
|
|
10,584
|
|
|
(60,883)
|
|
|
(31,900)
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sndl-reports-full-year-and-fourth-quarter-2023-financial-and-operational-results-302095542.html
SOURCE SNDL Inc.